Stay updated on Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial

Sign up to get notified when there's something new on the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    Change Detected
    Summary
    The page footer now displays Revision: v3.3.2, replacing the previous Revision: v3.2.0.
    Difference
    0.1%
    Check dated 2025-11-25T10:28:50.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The deletion removes the government funding/operating status notice that previously warned about updates and where to check for current information. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.6%
    Check dated 2025-11-18T06:52:13.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    The new screenshot shows cosmetic UI adjustments such as header spacing and minor layout tweaks; substantive study content and version history appear unchanged.
    Difference
    0.1%
    Check dated 2025-11-03T20:54:15.000Z thumbnail image
  6. Check
    67 days ago
    Change Detected
    Summary
    - Updated the page to include a government-operating-status notice and a new version tag (v3.2.0), replacing the old v3.1.0.
    Difference
    11%
    Check dated 2025-10-06T05:17:47.000Z thumbnail image
  7. Check
    74 days ago
    Change Detected
    Summary
    Changed the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.
    Difference
    0.3%
    Check dated 2025-09-29T02:58:56.000Z thumbnail image
  8. Check
    89 days ago
    Change Detected
    Summary
    Version updated from v3.0.1 to v3.0.2. The 'Back to Top' element was removed, a minor UI change with no impact on core content or functionality.
    Difference
    0.7%
    Check dated 2025-09-14T18:56:14.000Z thumbnail image

Stay in the know with updates to Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page.